重要内容提示： 青海春天药用资源科技股份有限公司（以下简称"公司"）股票交易在 2024 年 11 月 7 日、11 月 8 日、11 月 11 日连续 3 个交易日内日收盘价格涨幅偏离值累计达到 12%，属于股票交易异常波动。 经公司自查及向公司控股股东、实际控制人发函核实、确认，截至本公告披露 日，除公司已披露事项外，不存在其它应披露而未披露的重大事项。 股票代码：600381 股票简称：ST 春天 公告编号：2024-058 请广大投资者理性投资，注意股票二级市场的交易风险。 青海春天药用资源科技股份有限公司 关于股票交易异常波动的公告 一、股票交易异常波动的具体情况 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司股票交易在 2024 年 11 月 7 日、11 月 8 日、11 月 11 日连续 3 个交易日内日 收盘价格涨幅偏离值累计达到 12%，根据《上海证券交易所交易规则》的有关规定，属 于股票交易异常波动的情形。 二、公司关注并核实的相关情况 公司针对上述股票交易异常波动事项进行了自查，并向公司控股股东、 ...

股票代码：600381 股票简称：ST 春天 公告编号：2024-057 青海春天药用资源科技股份有限公司 关于股票交易风险的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 青海春天药用资源科技股份有限公司（以下简称"公司"）股价近期波动幅度较大， 公司特别提醒广大投资者注意二级市场交易风险，相关提示如下： 一、二级市场交易风险的提示 公司股票于 2024 年 11 月 7 日、11 月 8 日连续两个交易日涨停，波动幅度较大。 公司特别提醒广大投资者注意二级市场交易风险，理性决策，审慎投资。 二、生产经营风险的提示 公司于 2024 年 10 月 31 日披露了公司《2024 年第三季度报告》，2024 年 1-9 月营 业收入为 19,803.47 万元，同比增长 23.22%；归属于上市公司股东的净利润为- 9,045.18 万元、归属于上市公司股东扣除非经常性损益后的净利润为-8,970.92 万元， 公司业绩持续亏损。目前，公司生产经营情况正常，不存在影响公司股票交易价格大幅 波动的重大事项。 因公司最近 ...

Financial Performance - The company's operating revenue for Q3 2024 was ¥59,651,977.16, representing an increase of 11.94% compared to the same period last year[2]. - The net profit attributable to shareholders for Q3 2024 was -¥30,581,829.82, with a year-to-date net profit of -¥90,451,751.65[2]. - Total operating revenue for the first three quarters of 2024 reached ¥198,034,675.41, an increase of 23.1% compared to ¥160,712,654.06 in the same period of 2023[16]. - Net loss for the first three quarters of 2024 was ¥88,648,013.81, compared to a net loss of ¥68,576,421.15 in the same period of 2023, indicating a deterioration in financial performance[18]. - The basic and diluted earnings per share for Q3 2024 were both -¥0.053[3]. - The basic and diluted earnings per share for the first three quarters of 2024 were both -¥0.155, compared to -¥0.120 in the same period of 2023[19]. Cash Flow - The cash flow from operating activities for the year-to-date period was ¥19,456,771.80, showing a significant increase of 117.09%[3]. - Cash flow from operating activities was ¥188,407,604.97 for the first three quarters of 2024, compared to ¥174,195,469.42 in 2023, showing an increase of 8.2%[20]. - Operating cash inflow totaled CNY 193,069,418.50, an increase from CNY 179,140,626.75 in the previous period[21]. - Operating cash outflow amounted to CNY 173,612,646.70, compared to CNY 170,177,883.30 last year[21]. - Net cash flow from operating activities was CNY 19,456,771.80, up from CNY 8,962,743.45[21]. - The net increase in cash and cash equivalents was -CNY 28,556,812.86, compared to -CNY 6,749,165.61 last year[22]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,205,121,056.30, a decrease of 11.34% compared to the end of the previous year[3]. - The total assets of the company as of September 30, 2024, were RMB 1,205,121,056.30, down from RMB 1,359,312,015.51 at the end of 2023, a decrease of approximately 11.3%[13]. - The company's total liabilities decreased to ¥60,199,492.97 in Q3 2024 from ¥91,994,257.88 in Q3 2023, a reduction of 34.6%[15]. - The equity attributable to shareholders at the end of the reporting period was ¥1,140,866,373.20, down 9.82% from the previous year[3]. - The total equity attributable to shareholders decreased to ¥1,140,866,373.20 in Q3 2024 from ¥1,265,066,305.34 in Q3 2023, a decline of 9.8%[15]. Operational Efficiency - The company experienced a significant increase in cash flow from operating activities, indicating improved operational efficiency[3]. - The revenue growth in the reporting period was primarily driven by an increase in cash inflow from the sales of Cordyceps[9]. - The company reported a significant increase in payments to employees, totaling CNY 19,129,170.98, compared to CNY 17,571,263.51[21]. - Tax payments increased to CNY 16,625,130.74 from CNY 10,840,488.25 in the previous period[21]. Research and Development - Research and development expenses increased to ¥10,437,424.73 in 2024 from ¥7,554,555.90 in 2023, representing a growth of 38.5%[16]. - The company has not reported any new strategies or significant developments in product or technology research during the reporting period[10]. Shareholder Information - The top ten shareholders held a total of 41,252 shares, with the largest shareholder, Tibet Rong'en Technology Co., Ltd., owning 32.13% of the shares[9]. - The company has not disclosed any significant changes in the participation of major shareholders in margin trading or securities lending activities[10].

《问询函》的回复 青海春天药用资源科技股份有限公司: 贵公司关于股票交易异常波动的《问询函》我公司已收悉。我公 司就该《问询函》所关注事项回复、确认如下: 截至本回函日,我公司不存在其他买卖贵公司股票的情况、不存 在涉及贵公司的应披露而未披露的重大事项,包括但不限于筹划重大 资产重组、股份发行、债务重组、业务重组、资产剥离和资产注入等 重大事项。 专此回复。 对青海春天药用资源科技股份有限公司 西藏荣恩科技有限公司 对青海春天药用资源科技股份有限公司 《问询函》的回复 青海春天药用资源科技股份有限公司: 本人已收到贵司关于股票交易异常波动的《问询函》,并就该《问 询函》所关注事项回复、确认如下: 截至本回复日,本人不存在买卖贵公司股票、不存在涉及贵公司 的应披露而未披露的重大事项,包括但不限于筹划重大资产重组、股 份发行、债务重组、业务重组、资产剥离和资产注入等重大事项。 专此回复。 肖融 回复人 2024年10月8日 ...

股票代码：600381 股票简称：ST 春天 公告编号：2024-056 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 青海春天药用资源科技股份有限公司（以下简称"公司"）股票交易在 2024 年 9 月 27 日、9 月 30 日、10 月 8 日连续 3 个交易日内日收盘价格跌幅偏离值累计达到 12%，属于股票交易异常波动。 经公司自查及向公司控股股东、实际控制人发函核实、确认，截至本公告披露 日，除公司已披露事项外，不存在其它应披露而未披露的重大事项。 青海春天药用资源科技股份有限公司 关于股票交易异常波动的公告 公司近期日常经营情况和外部环境较前期未发生重大变化，公司不存在应披露而未 披露的重大信息，生产经营情况正常。 （二）重大事项情况 公司向控股股东及实际控制人发出问询函件，公司控股股东及实际控制人回函确认 除已披露信息外，不存在其它应披露而未披露的重大信息，包括但不限于筹划重大资 产重组、股份发行、债务重组、业务重组、资产剥离和资产注入等重大事项。 （三）媒体报道、市场传闻、热点概念情况 经核实 ...

股票代码：600381 股票简称：ST 春天 公告编号：2024-055 青海春天药用资源科技股份有限公司 关于全资子公司收到《行政处罚决定书》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 青海春天药用资源科技股份有限公司（以下简称"公司"）子公司西藏春天酒业有 限公司于近日收到西藏自治区市场监督管理局（以下简称"西藏市监局"）藏市监处罚 [2024]10 号《行政处罚决定书》。现将有关内容公告如下： 一、《行政处罚决定书》的主要内容 1.当事人 名称：西藏春天酒业有限公司 统一社会信用代码：91540091MA6T3CWU2R 3. 处罚的法律依据及处罚结果 依据《中华人民共和国反不正当竞争法》第二十条第一款的规定，参照《市场监 管总局关于规范市场监督管理行政处罚裁量权的指导意见》（国市监法规[2022]2 号） 第十条（四），以及《西藏自治区市场监督管理行政处罚裁量权适用规则及裁量基准》 的规定，责令当事人停止上述违法行为，并决定实施行政处罚如下：决定处罚款人民 币 1300000 元（大写：壹佰叁拾万元整）。 ...

经公司核实，公司在 2024 年 6 月 26 日实施回购的过程中，于 14 点 57 分至 15 点 收盘集合竞价期间进行回购股份的委托，累计成交 10 万股，成交价格 1.94 元/股，成 交总金额 19.40 万元。该回购操作系公司回购操作工作人员经验不足、操作失误所致， 并非主观故意违反《上海证券交易所上市公司自律监管指引第 7 号—回购股份（2023 年 12 月修订）》第十九条（二）的规定，也不存在利用回购股份操纵公司股价或进行利 益输送的情况。公司已高度重视上述事项发生的原因，将加强对有关工作人员的培训 及考核，确保后续各项工作遵守有关法律、法规和规范性文件的要求，并对由此给投资 者造成的不便致以歉意。 股票代码：600381 股票简称：ST 春天 公告编号：2024-054 青海春天药用资源科技股份有限公司 关于部分股份回购违规的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、回购股份的基本情况 青海春天药用资源科技股份有限公司（以下简称"公司"）于 2024 年 4 月 18 日召 开第九届董事会第 ...

Financial Performance - The company's operating revenue for the first half of 2024 was ¥138,382,698.25, representing an increase of 28.82% compared to the same period last year[14]. - The net profit attributable to shareholders of the listed company was -¥59,869,921.83, showing a decline from -¥50,590,714.14 in the previous year[14]. - The net cash flow from operating activities was ¥17,330,525.11, a significant improvement from -¥24,470,667.23 in the same period last year[14]. - The total assets at the end of the reporting period were ¥1,253,653,855.19, down 7.77% from ¥1,359,312,015.51 at the end of the previous year[14]. - The net assets attributable to shareholders of the listed company decreased by 5.76% to ¥1,192,186,435.83 from ¥1,265,066,305.34[14]. - The basic earnings per share for the first half of 2024 was -¥0.102, compared to -¥0.086 in the same period last year[15]. - The weighted average return on net assets was -4.87%, a decrease of 1.52 percentage points from -3.35% in the previous year[15]. - The company's main business revenue reached 135.50 million RMB, representing a year-on-year growth of 31.27%[17]. - The liquor segment achieved revenue of 50.001 million yuan, representing a year-on-year growth of 45.95%[18]. - The health segment generated revenue of 41.0934 million yuan, a year-on-year decrease of 25.16% due to the normalization of market demand for respiratory system drugs[18]. - The company reported a significant reduction in contract liabilities, down 65.11% to ¥14,086,157.84 from ¥40,378,116.52, indicating a decrease in advance payments received[26]. - The company’s total revenue for the first half of 2024 was approximately CNY 4.10 billion, a significant increase from CNY 73.39 million in the same period of 2023[65]. - The net loss attributable to the parent company for the first half of 2024 was CNY 59.87 million, compared to a loss of CNY 50.59 million in the same period of 2023[64]. Market and Business Strategy - The company has not disclosed any plans for new product development or market expansion in this report[5]. - The company has established a strategic layout for the efficient utilization of Cordyceps, focusing on health food and pharmaceutical products[17]. - The company plans to enhance sales of traditional Chinese medicine products containing Cordyceps, such as Li Fei Pian and Chong Cao Shen Qi Gao[17]. - The liquor business is primarily focused on high-end products, including the "Tinghua" series, which emphasizes health benefits and innovative brewing techniques[17]. - The company has recognized the growing demand for high-quality products in the liquor industry, aligning its business development with market trends[17]. - The company aims to strengthen cooperation with distributors to expand sales channels and improve product quality[22]. - The company plans to strengthen its two main business segments, focusing on the fast-moving consumer goods and health sectors to mitigate ongoing operational risks[34]. - The company is focusing on expanding its market presence and enhancing product development strategies[58]. Risk Management and Governance - The report includes a detailed description of potential external and internal risks faced by the company[3]. - The company has implemented a comprehensive internal governance system to standardize sales practices and support healthy growth[20]. - The company has actively engaged in R&D collaborations with renowned scientists and research institutions to foster long-term development[19]. - The company has implemented measures to reduce carbon emissions by improving energy efficiency and utilizing clean energy[42]. - The company has established a comprehensive emergency plan for environmental incidents, which includes risk assessment and response strategies[41]. - The company has established comprehensive internal governance regulations but acknowledges the need for ongoing improvements to adapt to external changes[33]. - The company is committed to enhancing internal control systems to mitigate ongoing operational risks as highlighted by the auditors[44]. Shareholder Information - The total number of ordinary shareholders as of the end of the reporting period is 44,865[50]. - The largest shareholder, Tibet Rong'en Technology Co., Ltd., holds 188,615,194 shares, accounting for 32.13% of the total shares[50]. - The second-largest shareholder, Xiao Rong, holds 56,762,789 shares, representing 9.67% of the total shares[50]. - The top three shareholders include Qinghai Spring Medicine Resources Technology Co., Ltd. with 5,436,100 shares, which is 0.93% of the total shares[50]. - The report indicates that there were no changes in the total number of shares or the capital structure during the reporting period[50]. - There are no significant changes in the shareholding structure or any major contracts that have not been disclosed[50]. - The company did not distribute dividends or increase capital reserves in the reporting period[38]. Environmental and Social Responsibility - The company has actively participated in environmental protection activities and promoted ecological awareness among employees[41]. - The company has reported no administrative penalties related to environmental issues during the reporting period[41]. - The company has a solid environmental monitoring system in place, combining automatic and manual monitoring methods[41]. Financial Management - The company maintains a low debt-to-asset ratio, ensuring smooth financing channels and strategic planning[20]. - The company has implemented a self-inspection and rectification process to improve its governance system and sales practices[21]. - The company reported a significant increase in cash flow management, with total cash and cash equivalents at ¥169,567,426.30 at the end of the period[142]. - The company has not reported any significant changes in the status of its financial assets, with no restrictions on the use of funds due to pledges or freezes[142]. - The company continues to focus on improving its credit risk management practices, as evidenced by the significant reversal of bad debt provisions[162]. Research and Development - Research and development expenses rose by 116.5% to ¥7,040,071.04, up from ¥3,251,810.73, mainly due to increased material usage[25]. - The company has successfully upgraded product flavors and consumer value through the "directed component editing" technology applied to aged liquor[19]. - The company has not reported any new significant projects or acquisitions during this period[179]. - The company's intangible assets formed through internal R&D accounted for 0% of the total intangible assets balance[182]. Taxation and Compliance - The company’s subsidiaries benefit from tax incentives, including a reduced corporate income tax rate of 15% for certain encouraged industries in Tibet[141]. - The company’s subsidiaries also enjoy a local tax exemption for enterprises employing over 70% of local residents until December 31, 2025[141]. - The company recorded a total tax payable of CNY 2,712,583.78 at the end of the period, down from CNY 6,905,916.54 at the beginning, representing a decrease of approximately 60.7%[200].

近日有媒体引用青海春天药用资源科技股份有限公司（以下简称"公司"）有 关部门负责人相关产品"不存在质量和食品安全问题"的表述进行报道。相关表述并非 有关市场监督管理部门《行政处罚决定书》的内容，有关《行政处罚决定书》的内容与 产品质量和食品安全问题无关。 公司股票交易在 2024 年 7 月 29 日、30 日、31 日连续 3 个交易日内日收盘价 格涨幅偏离值累计达到 12%，属于股票交易异常波动。截至 2024 年 8 月 1 日收盘，公 司股价剔除大盘整体因素后的实际波动幅度较大，特别提醒广大投资者理性投资，注 意股票二级市场的交易风险。 公司股价剔除大盘整体因素后的实际波动幅度较大，公司特别提醒广大投资者注 意有关的风险，相关提示如下： 股票代码：600381 股票简称：ST 春天 公告编号：2024-053 青海春天药用资源科技股份有限公司 关于股票交易风险提示的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、二级市场交易的风险 公司股票于 2024 年 7 月 29 日、30 日、31 日 ...

股票代码：600381 股票简称：ST 春天 公告编号：2024-052 青海春天药用资源科技股份有限公司 关于控股股东部分股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 青海春天药用资源科技股份有限公司（以下简称"公司"）控股股东西藏荣恩科 技有限公司（以下简称"西藏荣恩"）持有我公司 188,615,194 股无限售条件流通股， 占公司总股本的 32.13%。本次办理股份质押业务后，西藏荣恩累计质押数量为 11,362 万股，占其持股总数的 60.24%，占公司总股本的 19.35%。 西藏荣恩及其一致行动人肖融共持有公司股份 245,377,983 股，占我公司总股 本的 41.80%，累计质押数量（含本次）为 14,376 万股，占其持股总数的 58.59%，占公 司总股本的 24.49%。 一、 上市公司股份质押 公司于今日收到控股股东西藏荣恩关于其部分股份质押的通知，现将有关情况公 告如下： | 股东 | 是否为控 | 本次质 | 是否为 | 是否补 | 质押起 | 质押到 | 质权 ...